HRP20171927T1 - Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu - Google Patents

Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu Download PDF

Info

Publication number
HRP20171927T1
HRP20171927T1 HRP20171927TT HRP20171927T HRP20171927T1 HR P20171927 T1 HRP20171927 T1 HR P20171927T1 HR P20171927T T HRP20171927T T HR P20171927TT HR P20171927 T HRP20171927 T HR P20171927T HR P20171927 T1 HRP20171927 T1 HR P20171927T1
Authority
HR
Croatia
Prior art keywords
pharmacologically active
active ingredient
pain
pharmaceutical preparation
dosage form
Prior art date
Application number
HRP20171927TT
Other languages
English (en)
Inventor
Stefanie Frosch
Klaus Linz
Klaus Schiene
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HRP20171927T1 publication Critical patent/HRP20171927T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (13)

1. Farmaceutski pripravak, naznačen time što sadrži: (a) prvi farmakološki aktivni sastojak, koji se bira između kemijskog spoja kemijske formule (I) i njegovih fiziološki prihvatljivih soli. [image] (b) drugi farmakološki aktivni sastojak, koji se bira iz skupine koju čine acetilsalicilna kiselina i njene fiziološki prihvatljive soli.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1. naznačen time što je prvi farmakološki aktivni sastojak spoj kemijske formule (I) [image]
3. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži prvi i drugi farmakološki aktivni sastojak u takvom težinskom omjeru da posjeduju sinergistički terapijski učinak prilikom primjene na pacijentu.
4. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je relativni težinski omjer između prvog farmakološki aktivnog sastojka i drugog farmakološki aktivnog sastojka u rasponu od 1:30 do 1:1.000.000.
5. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju boli.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 5. naznačen time stoje bol: - periferna, centralna ili muskuloskeletalna bol; i/ili - akutna, subakutna ili kronična bol; i/ili - umjerena do jaka bol; i/ili - neuropatska ili psihogena ili nociceptivna ili miješana bol; i/ili - lumbalna bol, visceralna bol ili glavobolja; i/ili - postoperativna (nakon kirurškog zahvata), bol uzrokovana rakom ili upalna bol.
7. Farmaceutski oblik doziranja, naznačen time što sadrži farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva.
8. Farmaceutski oblik doziranja u skladu s patentnim zahtjevom 7, naznačen time što sadrži prvi farmakološki aktivni sastojak u dozi od 10 do 1.200 u.g.
9. Farmaceutski oblik doziranja u skladu s patentnim zahtjevom 7 ili 8. naznačen time što sadrži drugi farmakološki aktivni sastojak u dozi od 50 do 5.000 mg.
10. Farmaceutski oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 7 do 9, naznačen time stoje doza prvog farmakološki aktivnog sastojka u rasponu od 1:20 do 20:1 od količine koja je jednako djelotvorna kao doza drugog farmakološki aktivnog sastojka.
11. Farmaceutski oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 7 do 10, naznačen time što je namijenjen oralnoj, intravenskoj, intraperitonealnoj. transdermalnoj, intratekalnoj, intramuskularnoj, intranazalnoj, transmukozalnoj, supkutanoj ili rektalnoj primjeni.
12. Komplet, naznačen time što sadrži prvi farmaceutski oblik doziranja, naznačen time što sadrži prvi farmakološki aktivni sastojak u skladu s patentnim zahtjevom 1 ili 2, i a drugi farmaceutski oblik doziranja, naznačen time što sadrži drugi farmakološki aktivni sastojak u skladu s patentnim zahtjevom 1.
13. Komplet u skladu s patentnim zahtjevom 12, naznačen time što su prvi i drugi farmaceutski oblik doziranja prilagođeni za istodobnu ili uzastopnu primjenu, bilo istim ili različitim načinom primjene.
HRP20171927TT 2012-05-18 2013-05-16 Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu HRP20171927T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003936 2012-05-18
EP13723673.3A EP2852386B1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and acetylsalicylic acid
PCT/EP2013/001467 WO2013170968A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component

Publications (1)

Publication Number Publication Date
HRP20171927T1 true HRP20171927T1 (hr) 2018-01-26

Family

ID=48468207

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171927TT HRP20171927T1 (hr) 2012-05-18 2013-05-16 Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu

Country Status (22)

Country Link
US (1) US9855286B2 (hr)
EP (1) EP2852386B1 (hr)
JP (1) JP6116675B2 (hr)
CN (1) CN104284661A (hr)
AU (1) AU2013262074B2 (hr)
BR (1) BR112014028564A2 (hr)
CA (1) CA2873640A1 (hr)
CY (1) CY1119692T1 (hr)
DK (1) DK2852386T3 (hr)
EA (1) EA026642B1 (hr)
ES (1) ES2654146T3 (hr)
HR (1) HRP20171927T1 (hr)
HU (1) HUE035930T2 (hr)
IL (1) IL235656B (hr)
LT (1) LT2852386T (hr)
MX (1) MX352595B (hr)
NO (1) NO2852386T3 (hr)
PL (1) PL2852386T3 (hr)
PT (1) PT2852386T (hr)
RS (1) RS56674B1 (hr)
SI (1) SI2852386T1 (hr)
WO (1) WO2013170968A1 (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
IE55189B1 (en) 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
KR0156231B1 (ko) 1989-05-22 1998-11-16 존 레이 비핀 인도메타신의 2가 전이 금속염을 함유하는 조성물
CA2112378A1 (en) 1991-07-04 1993-01-21 Masakazu Kanazawa Analgesic preparation
US5339362A (en) 1992-01-07 1994-08-16 Rockford Corporation Automotive audio system
JPH05221857A (ja) 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
JPH08511522A (ja) 1993-06-07 1996-12-03 メルク エンド カンパニー インコーポレーテッド ニューロキニンアンタゴニストとしてのスピロ置換アザ環
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
DE69905380T2 (de) 1998-09-10 2003-11-27 Nycomed Danmark A/S, Roskilde Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
CA2350531A1 (en) 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
BR0307268A (pt) 2002-01-28 2004-12-14 Pfizer Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
EP1374906B1 (en) 2002-06-17 2007-04-18 CHIESI FARMACEUTICI S.p.A. A process for the preparation of piroxicam: beta-cyclodextrin inclusion compounds
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2612299A1 (en) 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
PL2012764T3 (pl) 2006-04-28 2011-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylopropylo)fenol i Paracetamol
CN101147735A (zh) 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
ES2416723T3 (es) 2007-10-09 2013-08-02 Merck Patent Gmbh Composiciones farmacéuticas que contienen benfotiamina y gabapentina
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
AR073277A1 (es) 2008-09-05 2010-10-28 Gruenenthal Gmbh Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol, y uso
AR073495A1 (es) 2008-09-05 2010-11-10 Gruenenthal Gmbh Combinacion farmaceutica que contiene el 6-dimetilaminometil-1- (3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid
KR101730924B1 (ko) 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
WO2012016703A2 (en) 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
AU2011287952B2 (en) 2010-08-04 2014-08-21 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane- 1,1'-pyrano[3,4,b]indol]-4-amine
KR20130097173A (ko) 2010-08-04 2013-09-02 그뤼넨탈 게엠베하 신경병증성 통증을 치료하기 위한 ６’­플루오로­（Ｎ­메틸­ 또는 Ｎ，Ｎ­디메틸­）­４­페닐­４’，９’­디하이드로­３’Ｈ­스피로[사이클로헥산­１，１’­피라노[３，４，ｂ]인돌]­４­아민을 포함하는 약제학적 투여형
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
FR3010236B1 (fr) 2013-09-05 2017-01-13 Arkema France Additifs pour ameliorer la conductivite ionique des electrodes de batteries li-ion

Also Published As

Publication number Publication date
IL235656B (en) 2018-08-30
JP6116675B2 (ja) 2017-04-19
EP2852386B1 (en) 2017-11-15
ES2654146T3 (es) 2018-02-12
BR112014028564A2 (pt) 2017-06-27
LT2852386T (lt) 2018-01-10
US20130317076A1 (en) 2013-11-28
JP2015516448A (ja) 2015-06-11
MX2014012765A (es) 2014-11-21
EA201401267A1 (ru) 2016-05-31
PL2852386T3 (pl) 2018-02-28
CY1119692T1 (el) 2018-04-04
PT2852386T (pt) 2018-01-04
EP2852386A1 (en) 2015-04-01
EA026642B1 (ru) 2017-04-28
MX352595B (es) 2017-11-30
WO2013170968A1 (en) 2013-11-21
AU2013262074A1 (en) 2015-01-22
HUE035930T2 (hu) 2018-06-28
NO2852386T3 (hr) 2018-04-14
AU2013262074B2 (en) 2018-01-18
SI2852386T1 (en) 2018-04-30
US9855286B2 (en) 2018-01-02
RS56674B1 (sr) 2018-03-30
DK2852386T3 (en) 2018-01-08
HK1204941A1 (en) 2015-12-11
IL235656A0 (en) 2015-01-29
CA2873640A1 (en) 2013-11-21
CN104284661A (zh) 2015-01-14

Similar Documents

Publication Publication Date Title
JP2013528600A5 (hr)
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP2012180381A5 (hr)
FI4406594T3 (fi) Kilpirauhashormonin analogeja
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
SG10201804024VA (en) Formulations of azaindole compounds
HRP20171693T1 (hr) Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
RU2014129508A (ru) Новая комбинация
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
JP2016505050A5 (hr)
HRP20171708T1 (hr) FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID
HRP20151340T1 (hr) Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije
SI2849744T1 (en) A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro (cyclohexane-1,1'-pyrano - (3,4, b) indol) -4-amine and duloxetine
HRP20171725T1 (hr) FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR
SI2849746T1 (en) A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro (cyclohexane-1,1'-pyrano- 3,4, b) indol) -4-amine and meloxicam
HRP20171927T1 (hr) Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.